Hosted on MSN1mon
Appeals court lifts halt on generic Entresto launch: report
A U.S. appeals court has lifted a temporary halt it imposed on the launch of a generic version of Novartis's (NYSE:NVS) top-selling cardiac drug Entresto. The U.S. Court of Appeals for the ...
Fed court rules against Novartis in generic Entresto case: report
A federal court in Delaware has reportedly ruled against Novartis (NYSE:NVS) in its quest to block the launch of a generic ...
pharmaphorum2d
Novartis’ Entresto set to transform heart failure treatment – and maybe pricing too
So Entresto is ready to be rolled out in the US with a price tag of around $4,500 a year. Novartis has hinted at an outcomes-based pricing plan but there are no details of any scheme or how it ...
pharmaphorum1y
Novartis will appeal Entresto patent setback
8,877,938 and 9,388,134). Litigation against Mylan and other companies hoping to bring generic versions of Entresto to the US market has been ongoing since 2019. Shares in Novartis, nevertheless ...